SNCA and Parkinson disease: Cutting the level of endogenous α-synuclein in PD patients has been suggested as a potential therapeutic approach to prevent the progression of the disease (Bae et al., 2012, Masliah et al., 2005, Masliah et al., 2011, Tran et al., 2014).